Anti-HIV drug design and therapy

被引：1
|
作者：
Ross, TM [1 ]
机构：
[1] Univ Pittsburgh, Sch Med, Div Infect Dis, Pittsburgh, PA 15261 USA
来源：
CURRENT PHARMACEUTICAL DESIGN | 2004年 / 10卷 / 32期
关键词：
D O I：
10.2174/1381612043382486
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：4003 / 4003
页数：1
相关论文
共 50 条
  • [1] ANTI-HIV THERAPY - SON IN DRUG DESIGN
    MANSURI, MM
    HITCHCOCK, MJM
    CHEMTECH, 1992, 22 (09) : 564 - 572
  • [2] Drug interactions and anti-HIV therapy
    Katende-Kyenda, N. L.
    Lubbe, M. S.
    Serfontein, J. H. P.
    Truter, I.
    JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2008, 33 (04) : 393 - 400
  • [3] Bioisosteric Replacement as a Tool in Anti-HIV Drug Design
    Dick, Alexej
    Cocklin, Simon
    PHARMACEUTICALS, 2020, 13 (03)
  • [4] Anti-HIV therapy
    Geraci, AP
    Di Rocco, A
    AIDS, 2000, 14 (13) : 2059 - 2061
  • [5] Intolerance to and/or drug interactions of anti-HIV and anti-HVC therapy
    Galpérine, T
    Merle, C
    de Truchis, P
    Bernard, L
    Perronne, C
    MEDECINE ET MALADIES INFECTIEUSES, 2005, 35 (03): : 135 - 140
  • [6] Developing G-quartet oligonucleotides as novel anti-HIV agents: focus on anti-HIV drug design
    Jing, NJ
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2000, 9 (08) : 1777 - 1785
  • [7] ANTI-HIV DRUG MECHANISM
    JONES, IM
    JACOB, GS
    NATURE, 1991, 352 (6332) : 198 - 198
  • [8] The Anti-HIV Drug Pipeline
    Bartlett, John G.
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2014, 65 : 48 - 48
  • [9] PROGRESS IN ANTI-HIV STRUCTURE-BASED DRUG DESIGN
    GAIT, MJ
    KARN, J
    TRENDS IN BIOTECHNOLOGY, 1995, 13 (10) : 430 - 438
  • [10] KINASE BYPASS - A NEW STRATEGY FOR ANTI-HIV DRUG DESIGN
    MCGUIGAN, C
    KINCHINGTON, D
    NICHOLLS, SR
    NICKSON, C
    OCONNOR, TJ
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 1993, 3 (06) : 1207 - 1210
12345